We have made considerable progress with Her2 targeting, especially in the first line, our Dr. Jaffer Ajani shared at #AACR26. Zanidatamab...

Back to meeting Original

Back to meeting

UT MD Anderson· @UTMDAnderson · X·2026-04-20 05:00· 2026-04-20Score60

zanidatamab

Reading

Next-generation ADCs: payload innovation

zanidatamab 新辅助 · No-chemo pCR 30%, HER2 down 56%

Body

We have made considerable progress with Her2 targeting, especially in the first line, our Dr. Jaffer Ajani shared at #AACR26. Zanidatamab/tislelizumab/chemo may be given to Her2 positive gastroesophageal adenocarcinoma patients, regardless of PDL-1 status. #EndCancer

Heat 17 · 13 likes · 0 replies · 4 reposts

Conference abstracts

4542matched by 药名 zanidatamab

Zanidatamab modulates multiple pathways involved in tumor growth and survival and is efficacious post T-DXd

Ankur Karmokar, Emanuele Loro, Al Hassan Kyakulaga, Desmond Lau, Nina Weisser, Genevieve Desjardins, Prajwal Raghunatha, Edwin Clark, Robin Humphreys, Kedar S. Vaidya

Read the abstract →

CT012matched by 药名 zanidatamab

A phase 2 single-arm open-label trial evaluating zanidatamab in patients with early stage HER2 positive breast cancer: The NeoZanHER Study

Vicente Valero, Paula R. Pohlmann, Jason Mouabbi, Xuelin Huang, Wei Qiao, Heather R. Alonzo, Rashmi Krishna Murthy, Gaiane M. Rauch, Taiwo Adesoye, Cristina M. Checka, William F. Symmans, Dmitri Grachev, Flora Alajajyan, Adaeze Nwosu-Iheme, Amy Hassan, Miral Mahesh Patel, Sharon H. Giordano, Kelly Hunt, Debasish Tripathy, Funda Meric-Bernstam

Read the abstract →

CT209NCT06695845matched by 代号 PAN-206

DiscovHER PAN-206: Phase 2 tumor-agnostic study of zanidatamab in patients with previously treated human epidermal growth factor receptor 2-overexpressing solid tumors

Vivek Subbiah, Vicky Makker, Do-Youn Oh, Elizabeth Gardener, Elaina Gartner, Funda Meric-Bernstam

Read the abstract →

Source: UT MD Anderson · x.com